NewAmsterdam Pharma (NAMS) Current Assets (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Current Assets of $658.0 million for Q1 2026, down 2.61% sequentially from $675.7 million in Q4 2025, and down 19.49% YoY from $817.3 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Current Assets (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Current Assets for 6 years, with the latest figure at $658.0 million in Q1 2026.
- Quarterly Current Assets fell 19.49% year-over-year to $658.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $658.0 million (down 19.49% YoY) and the FY2025 annual result came in at $675.7 million, down 21.74% from the prior year.
- Current Assets declined to $658.0 million in Q1 2026 per NAMS's latest filing, from $675.7 million in the prior quarter.
- Over five years, Current Assets peaked at $863.4 million in Q4 2024 and troughed at $423879.1 in Q2 2023.
- A 5-year average of $557.7 million and a median of $572.9 million in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets declined 24.15% in 2023, then soared 104965.82% in 2024.
- Over 5 years, Current Assets stood at $457.2 million in 2022, then decreased by 24.15% to $346.8 million in 2023, then jumped by 148.97% to $863.4 million in 2024, then slipped by 21.74% to $675.7 million in 2025, then slipped by 2.61% to $658.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $658.0 million, $675.7 million, and $732.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 659.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 659.21 Mn |
| Mar 31, 2026 | 658.04 Mn |
| Dec 31, 2025 | 675.70 Mn |
| Sep 30, 2025 | 732.33 Mn |
| Jun 30, 2025 | 769.85 Mn |
| Mar 31, 2025 | 817.30 Mn |
| Dec 31, 2024 | 863.41 Mn |
| Sep 30, 2024 | 437.87 Mn |
| Jun 30, 2024 | 445.35 Mn |
| Mar 31, 2024 | 487.82 Mn |
| Dec 31, 2023 | 346.79 Mn |
| Jun 30, 2023 | 423,879.06 |
| Dec 31, 2022 | 457.21 Mn |
| Dec 31, 2021 | 67.35 Mn |